Home > Insider Trading > Filing (0001493152-22-009000)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
876343	Lineage Cell Therapeutics Inc.	LCTX	Biological Products, (No Disgnostic Substances) (2836)	943127919

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1310683	M Brian Culley	2173 Salk Avenue, Suite 200 Carlsbad CA 92008	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares, No Par Value	Acquisiton	2022-03-31	15,450	$0.00	96,730	No	4	M	Direct
Common Shares, No Par Value	Disposition	2022-03-31	5,343	$1.54	91,387	No	4	F	Direct
Common Shares, No Par Value	Acquisiton	2022-03-31	6,400	$1.53	97,787	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Restricted Stock Units	Disposition	2022-03-31	15,450	$0.00	15,450	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,450			No	4	M	Direct

Footnotes

Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.
Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.